Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03609398 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine
A Phase 2 study of Rift Valley Fever, sponsored by U.S. Army Medical Research and Development Command.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT03609398: Recruiting Phase 2 study of Rift Valley Fever, sponsored by U.S. Army Medical Research and Development Command.
NCT03609398 is a Phase 2 study of Rift Valley Fever that is actively recruiting participants, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 500 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (276% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03609398, a Phase 2 study of Rift Valley Fever, is actively recruiting participants, sponsored by U.S. Army Medical Research and Development Command.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to collect safety and immunogenicity data for an Rift Valley Fever (RVF) vaccine
Primary Outcome
Safety assess of local and systemic adverse events and their relationship to the study vaccine. AEs will be recorded for 28 days after each dose of the vaccine for the assessment population (all subjects who receive at least one vaccination under this protocol. Subjects will be contacted by study staff via e-mail or telephone the day after vaccination (Day 1) and once per week for 4 weeks after each vaccination to discuss any reactions.
Conditions Studied
Interventions
- BIOLOGICAL RVF Vaccine
Study Locations (1)
Maryland
- Special Immunization Program, Division of Medicine, USAMRIID - Fort Deterick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2018-10-04 |
| Est. Completion | 2024-12 |
| Phase | Phase 2 |
What NCT03609398 shows while recruiting
NCT03609398 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (276% higher).
The record links to 1 condition, with Rift Valley Fever appearing as the primary indexed condition, and to 1 intervention - of which RVF Vaccine is the first listed.
NCT03609398 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03609398 about?
NCT03609398 is a clinical study titled "Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine". This study is to collect safety and immunogenicity data for an Rift Valley Fever (RVF) vaccine
What is the current status of trial NCT03609398?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2018-10-04. Estimated completion is 2024-12.
What conditions does trial NCT03609398 study?
This clinical trial studies the following conditions: Rift Valley Fever.
What interventions are being tested in trial NCT03609398?
The interventions under investigation include: RVF Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03609398?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03609398 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rift Valley Fever
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03609398's enrollment target sits among peer trials
500 70th of 2000 higher than 1,928 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI